Takeda Pharmaceutical Company Limited (TAK) Stock Price & Analysis
Takeda Pharmaceutical Company Limited (TAK) closed at USD 19.45 on Thursday, October 15, 2026, up 2.31% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 19.01; the Oct 15, 2026 session ranged USD 19.45–19.89 on volume of 4,197,090 shares. Market capitalization is $62.13B, with a 52-week range of USD 12.99–19.89 (NYQ). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TAK.md
Key facts (TAK)
- 1 of 80 tracked superinvestors hold TAK (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 22.77 (range 21.06–25.15).
- Total return with dividends: 1Y +40.1% vs S&P 500 +18.1%; 5Y +47.4% vs S&P 500 +85.1%.
- Next earnings: 2026-10-29, EPS estimate USD —, revenue estimate $1.15T.
Superinvestors (SEC 13F-HR, Q2 2026) (TAK)
1 of 80 tracked investors hold TAK. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | <0.01% | $606K | Added +33.4% |
Analysts (TAK)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 22.77 (low 21.06, high 25.15).
Total return (dividends reinvested) (TAK)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +40.1% | +47.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +40.3% | +8.0% |
| Volatility (annualized) | 21.2% | 18.4% |
| Max drawdown | -20.1% (Feb 2026→Jun 2026) | -24.7% (Apr 2023→Jun 2024) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 19.45 |
|---|---|
| Change | ▲ 2.31% (up) |
| Previous Close | USD 19.01 |
| Open | USD 19.58 |
| Day Range | USD 19.45 – 19.89 |
| 52-Week Range | USD 12.99 – 19.89 |
| Volume | 4,197,090 shares |
| Market Cap | $62.13B |
| Exchange | NYQ |
Technical Analysis (TAK)
Nexqual's technical model rates TAK "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.38 (neutral) |
| vs SMA50 | Above (USD 18.28) |
| MACD | 0.17 (positive) |
Analyst Ratings (TAK)
Wall Street analysts rate TAK "Buy" based on 3 analysts, with a mean price target of USD 22.77 (range USD 21.06–25.15), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 22.77 |
| High Target | USD 25.15 |
| Low Target | USD 21.06 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (TAK)
| Next Earnings Date | 2026-10-29 |
|---|---|
| Revenue Estimate | $1.15T |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (TAK)
| Total Revenue | $4.62T |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.20% |
| Gross Margin | +64.47% |
| Operating Margin | +16.45% |
| Profit Margin | -3.54% |
| ROE | -2.26% |
| Debt / Equity | 0.73 |
| Current Ratio | 1.14 |
| Total Cash | $460.98B |
| Total Debt | $5.54T |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (TAK)
Nexqual rates Takeda Pharmaceutical Company Limited's overall financial health "Solid" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +676% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 16% |
| Balance Sheet | Solid — JPY 461.0B cash vs JPY 5.54T debt |
| Cash Flow | Solid — Operating cash flow JPY 953.6B (TTM) |
| Efficiency | Critical — ROE -2%, ROA 2.7% |
Ownership (TAK)
| Insider Ownership | +0.08% |
|---|---|
| Institutional Ownership | +3.32% |
| Shares Outstanding | 3.19B |
| Float | 3.16B |
| Short % of Float | +0.09% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (TAK)
Takeda Pharmaceutical Company Limited is led by Julie Kim (age 55), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO, President & Director | Julie Kim (age 55) |
|---|---|
| CFO & Director | Milano Furuta (age 47) |
| President of Research & Development and Representative Director | Andrew S. Plump (age 60) |
| Chief Operating Officer | Michael Fox |
| Senior Vice President of Corporate Finance & Controlling Department | Iwaaki Taniguchi |
Major Backers & Investors (TAK)
Notable institutional backers of Takeda Pharmaceutical Company Limited include Capital Group, AMERICAN MUTUAL FUND, FMR, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 0.6% |
| AMERICAN MUTUAL FUND | 0.57% |
| FMR, LLC | 0.3% |
| Capital Income Builder | 0.23% |
| Morgan Stanley | 0.22% |
| Adage Capital Partners GP L.L.C. | 0.19% |
| Goldman Sachs | 0.18% |
| Brandes Investment Partners L.P. | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.12% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries | USD 41.11 | ▼ 0.34% |
| HLN | Haleon plc | USD 9.94 | ▲ 5.3% |
| ZTS | Zoetis Inc. | USD 78.42 | ▲ 5.55% |
| UTHR | United Therapeutics Corporation | USD 541.51 | ▼ 0.35% |
| VTRS | Viatris Inc. | USD 18.22 | ▲ 5.62% |
| NBIX | Neurocrine Biosciences, Inc. | USD 136.95 | ▲ 1.35% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt